<DOC>
	<DOCNO>NCT00053014</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy . Sometimes transplanted cell make immune response body 's normal tissue . Cyclosporine mycophenolate mofetil may prevent happen . PURPOSE : Phase II trial study effectiveness chemotherapy total-body irradiation follow donor peripheral stem cell transplantation , cyclosporine , mycophenolate mofetil treat old patient acute myeloid leukemia .</brief_summary>
	<brief_title>S0125 , Chemotherapy , Total-Body Irradiation , Peripheral Stem Cell Transplantation Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>Primary objective : - Determine whether allogeneic peripheral blood stem cell transplantation pre-conditioning low dose total body irradiation fludarabine follow cyclosporine mycophenolate mofetil , give elderly patient acute myeloid leukemia first complete remission , sufficiently efficacious ( term survival 1 year transplantation ) warrant phase III investigation . Secondary objective : - Determine frequency severity toxic effect regimen patient . Other objective fund permit : - Determine whether chimerism pattern bone marrow blood transplantation associate relapse and/or graft-versus-host disease ( GVHD ) patient . - Determine whether cytogenic , immunophenotypic , molecular biologic feature detect pre- post-transplantation specimen relate transplant outcome risk relapse patient . OUTLINE : This open-label study . - Conditioning regimen : Patients receive fludarabine IV 1 hour day -4 -2 . Patients also undergo total body irradiation day 0 . - Peripheral blood stem cell infusion ( PBSC ) : Patients receive unmodified filgrastim transplantation ( G-CSF ) -mobilized donor PBSC day 0 . - Post-transplantation immunosuppression : Patients receive oral cyclosporine day -3 35 followed taper day 180 . Patients also receive oral mycophenolate mofetil day 0 27 without taper . - Donor lymphocyte infusion ( DLI ) : Patients relapse disease receive DLI IV 30 minute 2 infusion . Patients follow every 3 month 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 25-51 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute myeloid leukemia ( AML ) ( within 180 day diagnosis ) OR Secondary AML ( secondary myelodysplastic syndrome ( MDS ) prior leukemogenic therapy ) Must A1 marrow , B1 blood , C1 extramedullary disease status Must receive prior remission induction chemotherapy Must genotypically HLAidentical sibling donor available monozygotic identical twin No M3 AML blastic transformation chronic myelogenous leukemia If history CNS leukemia , leukemia cell CNS lumbar puncture within past 7 day Must concurrently enrol protocol SWOG9007 SWOGS9910 PATIENT CHARACTERISTICS : Age 55 69 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No malignancy within past 2 year except follow : Adequately treat basal cell squamous cell skin cancer Carcinoma situ cervix Adequately treat stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy No prior allogeneic hematopoietic stem cell transplantation Chemotherapy See Disease Characteristics Prior consolidation therapy allow Endocrine therapy Not specify Radiotherapy Not specify Surgery Prior organ transplantation allow provide concurrently receive immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
</DOC>